On September 25, 2026, a registered clinical trial updated its status to active, not recruiting. The study, titled "A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension," is registered under identifier NCT04175600. It is listed as a Phase 3 trial evaluating selexipag as an add-on treatment alongside standard of care in pediatric patients with pulmonary arterial hypertension.
The active, not recruiting status indicates the study is ongoing but is no longer enrolling new participants. No results have been posted as part of this update. This brief reports only the trial's registered status, phase, title, and date as listed in the public record.
This update pertains to selexipag and its pediatric PAH indication, not to nesiritide directly. Readers interested in nesiritide should note it carries an unapproved research status and is not the subject of this particular registered trial. For background on nesiritide's development history and research context, readers can consult the compound overview page.